NEWS RELEASE

Merck Announces Supply Agreement with U.S.
Government for Molnupiravir, an Investigational Oral
Antiviral Candidate for Treatment of Mild toModerate COVID-19
6/9/2021

U.S. government commits to purchase approximately 1.7 million courses of Molnupiravir
upon issuance of Emergency Use Authorization or approval by the U.S. Food and Drug
Administration
KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced it has entered into a procurement agreement with the United States government formolnupiravir (MK-4482). Molnupiravir is currently being evaluated in a Phase 3 clinical trial, the MOVe-OUT study,
for the treatment of non-hospitalized patients with laboratory-con rmed COVID-19 and at least one risk factor
associated with poor disease outcomes. Merck is developing molnupiravir in collaboration with Ridgeback
Biotherapeutics.
“Merck is pleased to collaborate with the U.S. government on this new agreement that will provide Americans withCOVID-19 access to molnupiravir – an investigational oral therapy being studied for outpatient use early in thecourse of disease – if it is authorized or approved,” said Rob Davis, president, Merck. “In addition to this agreementwith the U.S. government, we are actively engaged in numerous e orts to make molnupiravir available globally toful ll Merck’s commitment to widespread access.”
Through the agreement, if molnupiravir receives Emergency Use Authorization (EUA) or approval by the U.S. Foodand Drug Administration (FDA), Merck will receive approximately $1.2 billion to supply approximately 1.7 million
1courses of molnupiravir to the United States government. Merck has been investing at risk to support development
and scale-up production of molnupiravir and expects to have more than 10 million courses of therapy available by
the end of 2021.
Merck also plans to submit applications for emergency use or approval to regulatory bodies outside of the U.S. andis currently in discussions with other countries interested in advance purchase agreements for molnupiravir. Merckis committed to providing timely access to molnupiravir globally and intends to implement a tiered pricing
approach based on World Bank data that recognizes countries’ relative ability to nance their public healthresponse to the pandemic.
As part of its access strategy, Merck has also entered into non-exclusive voluntary licensing agreements formolnupiravir with established generic manufacturers to accelerate availability of molnupiravir in 104 low- andmiddle-income countries (LMICs) following approvals or emergency authorization by local regulatory agencies.
In addition to developing molnupiravir, Merck is contributing to the pandemic response by collaborating withJohnson & Johnson to support the manufacture of its COVID-19 vaccine.
This procurement of molnupiravir will be supported in whole or in part with federal funds from the Department ofHealth and Human Services; O ce of the Assistant Secretary for Preparedness and Response; Biomedical
Advanced Research and Development Authority, in collaboration with the DOD Joint Program Executive O ce for
Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) under contract number W911QY21C0031.

About Molnupiravir
Molnupiravir (EIDD-2801/MK-4482) is an investigational, orally bioavailable form of a potent ribonucleoside analog
that inhibits the replication of multiple RNA viruses including SARS-CoV-2, the causative agent of COVID-19.
Molnupiravir has been shown to be active in several models of SARS-CoV-2, including for prophylaxis, treatment
and prevention of transmission, as well as SARS-CoV-1 and MERS. EIDD-2801 was invented at Drug Innovations atEmory (DRIVE), LLC, a not-for-pro t biotechnology company wholly owned by Emory University, and with partial
funding support from the U.S. government. Since licensed by Ridgeback, all funds used for the development ofEIDD-2801 by Ridgeback have been provided by Wayne and Wendy Holman and Merck.
The Phase 3 portion (Part 2) of the MOVe-OUT study, evaluating the potential of molnupiravir to reduce the risk ofhospitalization or death, is ongoing. Merck currently anticipates that, pending favorable results from MOVe-OUT,
the earliest possible submission for an Emergency Use Authorization for molnupiravir will be in the second half of2021. Merck and Ridgeback Biotherapeutics plan to share further ndings from the ongoing molnupiravir
development program with regulatory agencies as they become available. For more information on the2molnupiravir clinical trial please visit https://merckcovidresearch.com/.
In addition, Merck plans to initiate a clinical program to evaluate molnupiravir for post- exposure prophylaxis in thesecond half of 2021.

About Merck
For 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing
forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to saveand improve lives. We demonstrate our commitment to patients and population health by increasing access tohealth care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefrontof research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases
such as HIV and Ebola, and emerging animal diseases – as we aspire to be the premier research-intensive
biopharmaceutical company in the world. For more information, visit www.merck.com and connect with us on
Twitter, Facebook, Instagram, YouTube and LinkedIn.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA
This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements”
within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Thesestatements are based upon the current beliefs and expectations of the company’s management and are subject tosigni cant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products
will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying
assumptions prove inaccurate or risks or uncertainties materialize, actual results may di er materially from those
set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general
economic factors, including interest rate and currency exchange rate uctuations; the impact of the global outbreakof novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health carelegislation in the United States and internationally; global trends toward health care cost containment;
technological advances, new products and patents attained by competitors; challenges inherent in new productdevelopment, including obtaining regulatory approval; the company’s ability to accurately predict future marketconditions; manufacturing di culties or delays; nancial instability of international economies and sovereign risk;
dependence on the e ectiveness of the company’s patents and other protections for innovative products; and theexposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of3new information, future events or otherwise. Additional factors that could cause results to di er materially fromthose described in the forward-looking statements can be found in the company’s 2020 Annual Report on Form 10K and the company’s other lings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet
site (www.sec.gov).
View source version on businesswire.com: https://www.businesswire.com/news/home/20210609005142/en/
Media Contacts:
Melissa Moody(215) 407-3536
Investor Contacts:
Peter Dannenbaum(908) 740-1037
Raychel Kruper(908) 740-2107
Source: Merck & Co., Inc.

4